Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Interest Expenses (2020 - 2024)

Gyre Therapeutics (GYRE) has disclosed Interest Expenses for 9 consecutive years, with $315000.0 as the latest value for Q1 2024.

  • On a quarterly basis, Interest Expenses fell 51.01% to $315000.0 in Q1 2024 year-over-year; TTM through Dec 2024 was $315000.0, a 51.01% decrease, with the full-year FY2023 number at $2.6 million, changed N/A from a year prior.
  • Interest Expenses was $315000.0 for Q1 2024 at Gyre Therapeutics, down from $643000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $643000.0 in Q1 2023 to a low of $50000.0 in Q4 2020.
  • A 3-year average of $336000.0 and a median of $315000.0 in 2024 define the central range for Interest Expenses.
  • Biggest YoY gain for Interest Expenses was 51.01% in 2024; the steepest drop was 51.01% in 2024.
  • Gyre Therapeutics' Interest Expenses stood at $50000.0 in 2020, then skyrocketed by 1186.0% to $643000.0 in 2023, then tumbled by 51.01% to $315000.0 in 2024.
  • Per Business Quant, the three most recent readings for GYRE's Interest Expenses are $315000.0 (Q1 2024), $643000.0 (Q1 2023), and $50000.0 (Q4 2020).